Angèle Dilu-KetiTamara Tovar-SanchezBenjamin CuerAntoine Nkuba-NdayeDaniel Mukadi‐BamulekaEric Panzi-KalundaRichard Kitenge-OmasumbuJunior Bulabula-PengeFabrice Mambu-MbikaPlacide Mbala‐Kingebeni2026-03-222026-03-22202510.1093/ofid/ofaf436https://doi.org/10.1093/ofid/ofaf436https://andeanlibrary.org/handle/123456789/46789Citaciones: 1Despite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the REGN-EB3 group and musculoskeletal sequelae in the ZMapp group as compared with the remdesivir group, as well as among older survivors, women, and those with comorbidities. These results underscore the need for targeting long-term care to effectively manage post-Ebola sequelae.enMedicineEbola virusHazard ratioCohortProspective cohort studyOutbreakCohort studyPediatricsDiseaseInternal medicinearticle